Influence of C <i>YP2D6</i> Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole
CYP2D6 poor metabolism was associated with increased aripiprazole and aripiprazole plus dehydroaripiprazole concentrations-to-dose. CYP2D6 extreme phenotypes were associated with increased risk of treatment discontinuation over 1 year of treatment. This finding supports the applicability of pre-emptive CYP2D6 genotyping, which is expected to decrease aripiprazole adverse events and inefficacy that would probably lead to treatment discontinuation.
Authors
- Chin B. Eap (ORCID: https://orcid.org/0000-0002-5439-0230)
- Marianna Piras
- Séverine Crettol (ORCID: https://orcid.org/0000-0003-3790-7194)
- Stefan Kaiser (ORCID: https://orcid.org/0000-0002-3013-2034)
- Nicolas Ansermot (ORCID: https://orcid.org/0000-0001-8350-9416)
- François R. Girardin (ORCID: https://orcid.org/0000-0002-0842-927X)
- Kerstin Jessica Plessen (ORCID: https://orcid.org/0000-0001-5233-6145)
- Frederik Vandenberghe (ORCID: https://orcid.org/0000-0002-8964-2047)
- Armin von Gunten (ORCID: https://orcid.org/0000-0001-7852-3803)
- Setareh Ranjbar (ORCID: https://orcid.org/0000-0002-0238-2976)
- Franziska Gamma (ORCID: https://orcid.org/0000-0002-7991-466X)
- Carole Grandjean
- Cécile Gras
- Philippe Conus (ORCID: https://orcid.org/0000-0002-5832-1910)
- Claire Grosu
Institutions
- Université de Montpellier (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Addiction Switzerland (CH)
- Hôpital de Cery (CH)
- University Hospital of Geneva (CH)
- Association of Child Psychotherapists (GB)
- Geneva College (US)
- University of Lausanne (CH)
Publication Details
- Journal
- Schizophrenia Bulletin
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1093/schbul/sbaf076
- Citations
- 2
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 3.11
Funders
- National Research Foundation